Food and Drug Administration (2023) Examining off-label prescribing of Ozempic for weight loss, Qeios (2023) Wegovy (semaglutide): a new weight loss drug for chronic weight management, Journal of Investigative Medicine (2022) Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial, Diabetes Care (2018) Clinical insight on semaglutide for chronic weight management in adults: patient selection and special considerations, Drug Design, Development and Therapy (2022) Semaglutide, MedlinePlus (2023) Clinical insight on semaglutide for chronic weight management in adults: Patient selection and special considerations, Drug Design, Development and Therapy (2022) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

Retatrutide is a single-molecule triple agonist: It activates GIP, GLP-1, and glucagon receptors in one peptide
Options include increasing concentration, adding microneedling, incorporating other treatments like minoxidil, or switching to GHK-Cu to test whether the alternative copper peptide produces better individual response
*Compounded by an FDA-registered pharmacy
With NSAIDs: BPC-157 might counteract healing effects (the peptides cytoprotective mechanisms involve prostaglandin pathways)